Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo. (Q53424873)

14 May 2018

title

Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo. (English)

1 reference

14 May 2018

1 reference

F A Beland

1

1 reference

14 May 2018

L P McDaniel

series ordinal

2

1 reference

14 May 2018

M M Marques

series ordinal

3

1 reference

14 May 2018

language of work or name

English

0 references

publication date

1 March 1999

1 reference

14 May 2018

published in

Carcinogenesis

1 reference

14 May 2018

volume

20

1 reference

14 May 2018

issue

3

1 reference

14 May 2018

page(s)

471-477

1 reference

14 May 2018

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Tamoxifen-induced DNA adducts in leucocytes of breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Strong intensification of mouse hepatic tamoxifen DNA adduct formation by pretreatment with the sulfotransferase inhibitor and ubiquitous environmental pollutant pentachlorophenol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Tamoxifen: evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Activation of 4-hydroxytamoxifen and the tamoxifen derivative metabolite E by uterine peroxidase to form DNA adducts: comparison with DNA adducts formed in the uterus of Sprague-Dawley rats treated with tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Minor products of reaction of DNA with alpha-acetoxytamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Uterine peroxidase as a marker for estrogen action

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Hybridization of nuclear matrix attached deoxyribonucleic acid fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Nuclease P1-mediated enhancement of sensitivity of 32P-postlabeling test for structurally diverse DNA adducts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

DNA adduct formation after oral administration of 2-nitrofluorene and N-acetyl-2-aminofluorene, analyzed by 32P-TLC and 32P-HPLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

The colorimetric estimation of formaldehyde by means of the Hantzsch reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Tamoxifen associated uterine pathology in rodents: relevance to women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

The deuterium isotope effect for the alpha-hydroxylation of tamoxifen by rat liver microsomes accounts for the reduced genotoxicity of [D5-ethyl]tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Co-chromatography of a tamoxifen epoxide-deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

The pharmacology and clinical uses of tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Induction of CYP2B1 and 3A1, and associated monoxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

Risk of endometrial cancer after tamoxifen treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2F20.3.471

21 January 2018

Identifiers

DOI

10.1093/CARCIN/20.3.471

1 reference

14 May 2018

PubMed ID

10190564

1 reference

14 May 2018